DK0751957T3 - Peptid-fragmenter af mikrobielle stressproteiner og farmaceutisk sammensætning fremstillet deraf til behandling og forebyggelse af inflammatoriske sygdomme - Google Patents

Peptid-fragmenter af mikrobielle stressproteiner og farmaceutisk sammensætning fremstillet deraf til behandling og forebyggelse af inflammatoriske sygdomme

Info

Publication number
DK0751957T3
DK0751957T3 DK95912506T DK95912506T DK0751957T3 DK 0751957 T3 DK0751957 T3 DK 0751957T3 DK 95912506 T DK95912506 T DK 95912506T DK 95912506 T DK95912506 T DK 95912506T DK 0751957 T3 DK0751957 T3 DK 0751957T3
Authority
DK
Denmark
Prior art keywords
aminoacids
microbial
treatment
peptides
mammalian
Prior art date
Application number
DK95912506T
Other languages
Danish (da)
English (en)
Inventor
Der Zee Ruurd Van
Eden Willem Van
Stephen Mark Anderton
Original Assignee
Univ Utrecht
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utrecht filed Critical Univ Utrecht
Application granted granted Critical
Publication of DK0751957T3 publication Critical patent/DK0751957T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK95912506T 1994-03-21 1995-03-21 Peptid-fragmenter af mikrobielle stressproteiner og farmaceutisk sammensætning fremstillet deraf til behandling og forebyggelse af inflammatoriske sygdomme DK0751957T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP94200721 1994-03-21
EP94200738 1994-03-22
EP94202927 1994-10-10
PCT/NL1995/000108 WO1995025744A1 (en) 1994-03-21 1995-03-21 Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases

Publications (1)

Publication Number Publication Date
DK0751957T3 true DK0751957T3 (da) 2004-06-01

Family

ID=27235971

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95912506T DK0751957T3 (da) 1994-03-21 1995-03-21 Peptid-fragmenter af mikrobielle stressproteiner og farmaceutisk sammensætning fremstillet deraf til behandling og forebyggelse af inflammatoriske sygdomme

Country Status (10)

Country Link
EP (1) EP0751957B1 (de)
JP (2) JPH09511239A (de)
AT (1) ATE260295T1 (de)
AU (1) AU699007B2 (de)
CA (1) CA2185826C (de)
DE (1) DE69532605T2 (de)
DK (1) DK0751957T3 (de)
ES (1) ES2216009T3 (de)
PT (1) PT751957E (de)
WO (1) WO1995025744A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9419553D0 (en) * 1994-09-27 1994-11-16 Univ Bristol Polypeptides and their use in the treatment of auto-immune disease
GB9519737D0 (en) * 1995-09-27 1995-11-29 Peptide Therapeutics Ltd Polypeptides and their use in treatment and prophylaxis of auto-immune
US5985287A (en) * 1996-08-29 1999-11-16 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6284255B1 (en) * 1996-08-29 2001-09-04 Genesis Research & Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US5968524A (en) * 1997-12-23 1999-10-19 Genesis Research & Development Corp. Methods and compounds for the treatment of immunologically-mediated psoriasis
EP0947524A1 (de) * 1998-03-30 1999-10-06 Upither B.V. Neue Peptide zur Behandlung von Autoimmunkrankheiten
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
ES2257082T3 (es) 1998-11-05 2006-07-16 HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO. LTD. Nuevas secuencias de aminoacidos, adn que codifica las secuencias de aminoacidos, anticuerpos dirigidos contra tales secuencias y los diferentes usos de ello.
US7488476B2 (en) 1998-11-05 2009-02-10 Hadasit Medical Research Services & Development Ltd. B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases
US8158125B2 (en) 1998-11-05 2012-04-17 Hadasit Medical Research Services & Development Ltd. B-cell epitope peptides of HSP 65, novel amino acid sequences, DNA encoding the amino acid sequences of said peptides, antibodies directed against said peptides and different uses thereof in the treatment of inflammatory and autoimmune diseases
US6638518B1 (en) * 1999-02-22 2003-10-28 University Of Iowa Research Foundation Method for inhibiting inflammatory responses
IL132611A0 (en) 1999-10-27 2001-03-19 Yeda Res & Dev Synthetic genes and polypeptides and pharmaceutical compositions comprising them
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US7608683B2 (en) 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
EP1652856A1 (de) * 2000-08-09 2006-05-03 The Regents of The University of California San Diego Stressproteine-abgeleitete Peptide und Verfahren zu deren Verwendung
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
EP1575479A4 (de) 2002-01-31 2006-10-25 Develogen Israel Ltd Hsp-peptide und analoga zur modulation von immunantworten über antigen präsentierende zellen
WO2006072946A2 (en) 2005-01-04 2006-07-13 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
CN101801402B (zh) 2007-07-06 2013-08-28 乌得勒支大学控股有限公司 炎性疾病和自身免疫疾病的治疗和预防
BR122019024895B8 (pt) 2008-06-26 2021-07-27 Orphazyme As uso de um agente bioativo capaz de aumentar a concentração intracelular de hsp70
JP5350996B2 (ja) * 2009-11-25 2013-11-27 バブコック日立株式会社 酸素燃焼システムの排ガス処理装置
CN103338784A (zh) 2010-11-30 2013-10-02 奥菲泽米有限公司 用于增加Hsp70细胞内活性的方法
PL3193840T3 (pl) 2014-09-15 2021-12-06 Orphazyme A/S Preparat arimoklomolu
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
CN109069496A (zh) 2016-04-29 2018-12-21 奥菲泽米有限公司 用于治疗葡糖脑苷脂酶相关疾病的arimoclomol
NZ800483A (en) 2020-11-19 2024-03-22 Zevra Denmark As Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8701163A (nl) * 1986-09-09 1988-04-05 Nederlanden Staat Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits.
US4952395A (en) * 1987-02-26 1990-08-28 Scripps Clinic And Research Foundation Mycobacterial recombinants and peptides
NL8703107A (nl) * 1987-12-22 1989-07-17 Nederlanden Staat Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten.
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
CA2071896A1 (en) * 1990-09-06 1992-03-07 Willem Van Eden Inhibitor of lymphocyte response and immune-related disease

Also Published As

Publication number Publication date
DE69532605D1 (de) 2004-04-01
CA2185826C (en) 2007-06-19
DE69532605T2 (de) 2005-02-17
CA2185826A1 (en) 1995-09-28
PT751957E (pt) 2004-07-30
AU699007B2 (en) 1998-11-19
WO1995025744A1 (en) 1995-09-28
JP2007000147A (ja) 2007-01-11
EP0751957A1 (de) 1997-01-08
EP0751957B1 (de) 2004-02-25
ES2216009T3 (es) 2004-10-16
AU1962895A (en) 1995-10-09
JPH09511239A (ja) 1997-11-11
ATE260295T1 (de) 2004-03-15

Similar Documents

Publication Publication Date Title
DK0751957T3 (da) Peptid-fragmenter af mikrobielle stressproteiner og farmaceutisk sammensætning fremstillet deraf til behandling og forebyggelse af inflammatoriske sygdomme
Atoda et al. The primary structure of coagulation factor IX/factor X-binding protein isolated from the venom of Trimeresurus flavoviridis. Homology with asialoglycoprotein receptors, proteoglycan core protein, tetranectin, and lymphocyte Fc epsilon receptor for immunoglobulin E
Hirabayashi et al. Complete primary structure of a galactose-specific lectin from the venom of the rattlesnake Crotalus atrox. Homologies with Ca2 (+)-dependent-type lectins
PT672145E (pt) Polipeptideos de interleucina-3(il-3) com multiplas mutacoes
EA199800973A1 (ru) Полипептид белка-106 наружной мембраны moraxella catarrhalis, последовательность гена и их применение
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
ATE336511T1 (de) Peptide und peptidomimetika mit struktureller ähnlichkeit mit p53 und die die p53-funktion aktivieren
DE68916932D1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
DE10075019I2 (de) Neue Proteine mit TNF-Hemmender Wirkung und ihre Herstellung.
BR9914066A (pt) Polipeptìdio degradador de c3 de complemento humano de streptococcus pneumoniae
Alsenz et al. Phylogeny of the third component of complement, C3: analysis of the conservation of human CR1, CR2, H, and B binding sites, concanavalin A binding sites, and thiolester bond in the C3 from different species
HUP9901688A2 (hu) A diabétesz kezelésére szolgáló, humán hősokk protein 60-ból származó új peptidek, készítmények, eljárások és kitek
HUT69169A (en) T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
ATE282634T1 (de) Chaperonin 10
Southan et al. Amino acid sequence of β‐galactoside‐binding bovine heart lectin: Member of a novel class of vertebrate proteins
CA2351558A1 (en) Peptide fragments having cell death inhibitory activity
ATE357526T1 (de) Modifizierte hcv peptid-impfstoffe
DK0667781T3 (da) Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier
ATE183652T1 (de) Synthetische peptide für die behandlung von myasthenia gravis
Fairwell et al. Acetylated N‐terminal structures of class III alcohol dehydrogenases Differences among the three enzyme classes
NO960748L (no) Rekombinante Alternaria alternata allergener
Debuire et al. Structural studies of human IgD